802 related articles for article (PubMed ID: 25877605)
21. Second trimester maternal serum D-dimer combined with alpha-fetoprotein and free β-subunit of human chorionic gonadotropin predict hypertensive disorders of pregnancy: a systematic review and retrospective case-control study.
Chen Y; Chen Y; Wang X; Chu X; Ning W; Gu L; Li L; Xie Z; Wen C
J Transl Med; 2021 Mar; 19(1):94. PubMed ID: 33653375
[TBL] [Abstract][Full Text] [Related]
22. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
Liao S; Wang Y; Ye G
Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of combined serum biomarkers for adverse pregnancy outcomes.
Cohen JL; Smilen KE; Bianco AT; Moshier EL; Ferrara LA; Stone JL
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():89-94. PubMed ID: 25129153
[TBL] [Abstract][Full Text] [Related]
24. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C; Gallo DM; Gonzalez R; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Sep; 46(3):341-9. PubMed ID: 25969963
[TBL] [Abstract][Full Text] [Related]
25. Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels.
Räty R; Koskinen P; Alanen A; Irjala K; Matinlauri I; Ekblad U
Prenat Diagn; 1999 Feb; 19(2):122-7. PubMed ID: 10215068
[TBL] [Abstract][Full Text] [Related]
26. Second Trimester Serum Biomarker Screen for Fetal Aneuploidies as a Predictor of Preterm Delivery: A Population-Based Study.
Nunthapiwat S; Sekararithi R; Wanapirak C; Sirichotiyakul S; Tongprasert F; Srisupundit K; Luewan S; Tongsong T
Gynecol Obstet Invest; 2019; 84(4):326-333. PubMed ID: 30602167
[TBL] [Abstract][Full Text] [Related]
27. Association Analysis between Maternal Serum Biomarkers and Fetal Congenital Heart Disease.
Jiang H; Lin Y; He X
Heart Surg Forum; 2023 Oct; 26(5):E552-E559. PubMed ID: 37920073
[TBL] [Abstract][Full Text] [Related]
28. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
29. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia.
Di Lorenzo G; Ceccarello M; Cecotti V; Ronfani L; Monasta L; Vecchi Brumatti L; Montico M; D'Ottavio G
Placenta; 2012 Jun; 33(6):495-501. PubMed ID: 22459245
[TBL] [Abstract][Full Text] [Related]
30. First and second trimester markers of fetal aneuploidy in pregnant women with HIV infection.
Spencer K
Fetal Diagn Ther; 2011; 29(2):135-8. PubMed ID: 20714121
[TBL] [Abstract][Full Text] [Related]
31. Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A; Guerra L; Pellegrino M; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jun; 47(6):762-7. PubMed ID: 26726121
[TBL] [Abstract][Full Text] [Related]
32. Midtrimester N-terminal proatrial natriuretic peptide, free beta hCG, and alpha-fetoprotein in predicting preeclampsia.
Pouta AM; Hartikainen AL; Vuolteenaho OJ; Ruokonen AO; Laatikainen TJ
Obstet Gynecol; 1998 Jun; 91(6):940-4. PubMed ID: 9611000
[TBL] [Abstract][Full Text] [Related]
33. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome.
Huang T; Hoffman B; Meschino W; Kingdom J; Okun N
Prenat Diagn; 2010 May; 30(5):471-7. PubMed ID: 20440736
[TBL] [Abstract][Full Text] [Related]
34. First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy.
Svirsky R; Levinsohn-Tavor O; Feldman N; Klog E; Cuckle H; Maymon R
Ultrasound Obstet Gynecol; 2016 May; 47(5):560-4. PubMed ID: 25865365
[TBL] [Abstract][Full Text] [Related]
35. The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down's syndrome.
Kim SY; Kim SK; Lee JS; Kim IK; Lee K
Yonsei Med J; 2000 Apr; 41(2):226-9. PubMed ID: 10817024
[TBL] [Abstract][Full Text] [Related]
36. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
37. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-HCG.
Chen Y; Huang J; Mei J
Clin Biochem; 2019 Jul; 69():21-25. PubMed ID: 31152694
[TBL] [Abstract][Full Text] [Related]
38. Elevated second-trimester maternal serum β-human chorionic gonadotropin and amniotic fluid alpha-fetoprotein as indicators of adverse obstetric outcomes in fetal Turner syndrome.
Alvarez-Nava F; Soto M; Lanes R; Pons H; Morales-Machin A; Bracho A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1891-8. PubMed ID: 26369382
[TBL] [Abstract][Full Text] [Related]
39. The predictive value of maternal serum AFP to PAPP-A or b-hCG ratios in spontaneous preterm birth.
Celik E; Melekoğlu R; Baygül A; Kalkan U; Şimşek Y
J Obstet Gynaecol; 2022 Aug; 42(6):1956-1961. PubMed ID: 35620869
[TBL] [Abstract][Full Text] [Related]
40. A preeclampsia risk prediction model based on maternal characteristics and serum markers in twin pregnancy.
Kim YR; Jung I; Heo SJ; Chang SW; Cho HY
J Matern Fetal Neonatal Med; 2021 Nov; 34(21):3623-3628. PubMed ID: 31739715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
